Rezolute公司宣布,其针对先天性高胰岛素血症患者的三期Sunrize临床试验中Ersodetug的研究成果,将于儿科内分泌学会年度会议上以口头报告形式呈现。这项重要研究数据的披露,标志着公司在罕见病治疗领域取得的关键进展。
Rezolute公司宣布,其针对先天性高胰岛素血症患者的三期Sunrize临床试验中Ersodetug的研究成果,将于儿科内分泌学会年度会议上以口头报告形式呈现。这项重要研究数据的披露,标志着公司在罕见病治疗领域取得的关键进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.